Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29938710 | 0.88 | CYP26A1 (0.46) | KMT2ATBXAS1CYP1A2USP2LMNA | |
| SCHEMBL20754590 | 0.77 | CYP2D6 (0.39) | KMT2ACYP1A2LMNAMEN1CYP2D6 | |
| SCHEMBL6981241 | 0.77 | RAB9A (0.41) | KMT2ANPC1RAB9AHDAC1 | |
| SCHEMBL6037395 | 0.76 | KMT2A (0.47) | KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6432858 | 0.75 | KMT2A (0.46) | KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20746395 | 0.74 | RAB9A (0.49) | KMT2ACYP1A2LMNAMEN1NPC1 | |
| SCHEMBL20746392 | 0.74 | RAB9A (0.49) | KMT2ACYP1A2LMNAMEN1NPC1 | |
| SCHEMBL11056041 | 0.73 | PIK3CA (0.48) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20746574 | 0.72 | NPC1 (0.51) | KMT2ALMNAMEN1NPC1RAB9A | |
| SCHEMBL20746436 | 0.71 | KMT2A (0.51) | KMT2ACYP1A2LMNAMEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11510905-B1 | Pleuromutilin (E)-4-(1-imidazoylmethyl)cinnamic acid ester with anti-drug resistant bacteria activity and a method of preparing the same | SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2022-11-29 | — | — | US | disclosed |
| US-20220354826-A1 | PLEUROMUTILIN (E)-4-(1-IMIDAZOYLMETHYL )CINNAMIC ACID ESTER WITH ANTI-DRUG RESISTANT BACTERIA ACTIVITY AND A METHOD OF PREPARING THE SAME | SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11510905-B1 | Pleuromutilin (E)-4-(1-imidazoylmethyl)cinnamic acid ester with anti-drug resistant bacteria activity and a method of preparing the same | PLEC, MRPL21, MIF | KMT2A 3538/4885TBXAS1 3402/4885CYP1A2 2267/4885 |
| US-20220354826-A1 | PLEUROMUTILIN (E)-4-(1-IMIDAZOYLMETHYL )CINNAMIC ACID ESTER WITH ANTI-DRUG RESISTANT BACTERIA ACTIVITY AND A METHOD OF PREPARING THE SAME | PLEC, MRPL21, MIF | KMT2A 3538/4885TBXAS1 3402/4885CYP1A2 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.